A high-throughput assay using dengue-1 virus-like particles for drug discovery

Min Qing, Wei Liu, Zhiming Yuan, Feng Gu, Pei-Yong Shi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Dengue virus (DENV) is a mosquito-borne flavivirus responsible for 50-100 million human infections each year. The development of DENV chemotherapy requires high-throughput screening (HTS) assays. A dengue virus-like particle (VLP) has been constructed using viral structural proteins to package a Renilla luciferase reporter replicon. VLP could be produced by either the sequential electroporation of the replicon RNAs and the structural gene RNAs or by electroporating replicon RNA into a stable cell line expressing the structural proteins. In both approaches, the key to produce high titer VLP (3×106foci-forming unit/ml) is to use low temperature (30°C) in the packaging step. In addition, exogenous expression of host protease furin increased VLP infectivity. The infection could be blocked by antibodies against viral envelope protein and by an inhibitor of viral NS5 polymerase, but not by an inhibitor of host alpha-glucosidase (castanospermine). The VLP infection assay was optimized for HTS in a 384-well format with consistent and robust signal, providing a simple and rapid cell-based assay for screening inhibitors against DENV entry, translation, and replication in an HTS format.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalAntiviral Research
Volume86
Issue number2
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Dengue Virus
Drug Discovery
Virion
Replicon
RNA
Renilla Luciferases
Infection
Furin
High-Throughput Screening Assays
Viral Envelope Proteins
Viral Structural Proteins
Flavivirus
Virus Internalization
Electroporation
Product Packaging
Virus Replication
Culicidae
Peptide Hydrolases
Drug Therapy
Cell Line

Keywords

  • Dengue
  • HTS (high-throughput screen)
  • Luciferase reporter
  • VLP (virus-like particle)

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

A high-throughput assay using dengue-1 virus-like particles for drug discovery. / Qing, Min; Liu, Wei; Yuan, Zhiming; Gu, Feng; Shi, Pei-Yong.

In: Antiviral Research, Vol. 86, No. 2, 05.2010, p. 163-171.

Research output: Contribution to journalArticle

Qing, Min ; Liu, Wei ; Yuan, Zhiming ; Gu, Feng ; Shi, Pei-Yong. / A high-throughput assay using dengue-1 virus-like particles for drug discovery. In: Antiviral Research. 2010 ; Vol. 86, No. 2. pp. 163-171.
@article{d02f1d8fd593449cae37af964db2e031,
title = "A high-throughput assay using dengue-1 virus-like particles for drug discovery",
abstract = "Dengue virus (DENV) is a mosquito-borne flavivirus responsible for 50-100 million human infections each year. The development of DENV chemotherapy requires high-throughput screening (HTS) assays. A dengue virus-like particle (VLP) has been constructed using viral structural proteins to package a Renilla luciferase reporter replicon. VLP could be produced by either the sequential electroporation of the replicon RNAs and the structural gene RNAs or by electroporating replicon RNA into a stable cell line expressing the structural proteins. In both approaches, the key to produce high titer VLP (3×106foci-forming unit/ml) is to use low temperature (30°C) in the packaging step. In addition, exogenous expression of host protease furin increased VLP infectivity. The infection could be blocked by antibodies against viral envelope protein and by an inhibitor of viral NS5 polymerase, but not by an inhibitor of host alpha-glucosidase (castanospermine). The VLP infection assay was optimized for HTS in a 384-well format with consistent and robust signal, providing a simple and rapid cell-based assay for screening inhibitors against DENV entry, translation, and replication in an HTS format.",
keywords = "Dengue, HTS (high-throughput screen), Luciferase reporter, VLP (virus-like particle)",
author = "Min Qing and Wei Liu and Zhiming Yuan and Feng Gu and Pei-Yong Shi",
year = "2010",
month = "5",
doi = "10.1016/j.antiviral.2010.02.313",
language = "English (US)",
volume = "86",
pages = "163--171",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - A high-throughput assay using dengue-1 virus-like particles for drug discovery

AU - Qing, Min

AU - Liu, Wei

AU - Yuan, Zhiming

AU - Gu, Feng

AU - Shi, Pei-Yong

PY - 2010/5

Y1 - 2010/5

N2 - Dengue virus (DENV) is a mosquito-borne flavivirus responsible for 50-100 million human infections each year. The development of DENV chemotherapy requires high-throughput screening (HTS) assays. A dengue virus-like particle (VLP) has been constructed using viral structural proteins to package a Renilla luciferase reporter replicon. VLP could be produced by either the sequential electroporation of the replicon RNAs and the structural gene RNAs or by electroporating replicon RNA into a stable cell line expressing the structural proteins. In both approaches, the key to produce high titer VLP (3×106foci-forming unit/ml) is to use low temperature (30°C) in the packaging step. In addition, exogenous expression of host protease furin increased VLP infectivity. The infection could be blocked by antibodies against viral envelope protein and by an inhibitor of viral NS5 polymerase, but not by an inhibitor of host alpha-glucosidase (castanospermine). The VLP infection assay was optimized for HTS in a 384-well format with consistent and robust signal, providing a simple and rapid cell-based assay for screening inhibitors against DENV entry, translation, and replication in an HTS format.

AB - Dengue virus (DENV) is a mosquito-borne flavivirus responsible for 50-100 million human infections each year. The development of DENV chemotherapy requires high-throughput screening (HTS) assays. A dengue virus-like particle (VLP) has been constructed using viral structural proteins to package a Renilla luciferase reporter replicon. VLP could be produced by either the sequential electroporation of the replicon RNAs and the structural gene RNAs or by electroporating replicon RNA into a stable cell line expressing the structural proteins. In both approaches, the key to produce high titer VLP (3×106foci-forming unit/ml) is to use low temperature (30°C) in the packaging step. In addition, exogenous expression of host protease furin increased VLP infectivity. The infection could be blocked by antibodies against viral envelope protein and by an inhibitor of viral NS5 polymerase, but not by an inhibitor of host alpha-glucosidase (castanospermine). The VLP infection assay was optimized for HTS in a 384-well format with consistent and robust signal, providing a simple and rapid cell-based assay for screening inhibitors against DENV entry, translation, and replication in an HTS format.

KW - Dengue

KW - HTS (high-throughput screen)

KW - Luciferase reporter

KW - VLP (virus-like particle)

UR - http://www.scopus.com/inward/record.url?scp=77951298609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951298609&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2010.02.313

DO - 10.1016/j.antiviral.2010.02.313

M3 - Article

VL - 86

SP - 163

EP - 171

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 2

ER -